ADMA Biologics, Inc. (ADMA) Deep Dive Video

ADMA offers differentiated ASCENIV-driven specialty biologics upside, but investors must weigh strong margins and clinical niche value against pricing pressure, distributor concentration, litigation risk, and damaged guidance credibility.